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Abstract
Antiphospholipid syndrome (APS) is defined by the association of autoantibodies to certain
phospholipid-binding proteins with arterial or venous thrombosis (‘AT’ or ‘VT’, respectively),
and/or pregnancy-related morbidity (PM). Antiphospholipid antibodies (aPLA) promote activation
of several cell types including monocytes, resulting in procoagulant tissue factor (TF) expression
that may contribute to the vascular complications. Since TF synthesis by monocytes is frequently
accompanied by release of TF-bearing microparticles, we hypothesized that plasma microparticle
TF activity (MP-TF) may be elevated in APS patients and contribute to thrombosis and/or PM.
Platelet-poor plasma specimens were obtained from 30 patients with definite APS and 72 patients
with asymptomatic aPLA from the Antiphospholipid Syndrome Collaborative Registry
(APSCORE). MP-TF was measured by an in-house factor Xa generation assay. The two groups
were well matched for gender, age, ethnicity, proportions with underlying SLE, and aPLA
profiles. MP-TF (median and (IQR)) in asymptomatic aPLA subjects was 0.09 pg/mL (0.05–0.14)
compared to 0.13 pg/mL (0.10–0.17) in APS (p<0.001). No differences in MP-TF levels were
observed between APS subjects with PM, thrombosis, or PM + thrombosis. Similarly, among
subjects with either APS or asymptomatic aPLA, MP-TF did not differ in the presence or absence
of underlying SLE. Prospective studies will be required to determine if plasma MP-TF activity is
causally related to thrombotic or gestational complications in APS.
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Antiphospholipid syndrome (APS) is a term used to describe the association of
autoantibodies directed against phospholipid-binding proteins with adverse clinical
outcomes such as AT or VT, or pregnancy-related morbidity PM1. International consensus
classification criteria for definite APS were first published in 1999 and subsequently revised
in 20062.
It is also apparent that aPLA may be incidentally detected in a small proportion of the
healthy population. These individuals may be at increased risk of thrombosis compared to
the general population3. However, given that many subjects with persistent aPLA remain
asymptomatic, prognostic markers capable of estimating the individual risk of developing
thrombosis would be of potentially great utility.
Tissue factor (TF) is a transmembrane glycoprotein that in complex with factor VII(a)
initiates coagulation and is essential for haemostasis. There is growing evidence that
aberrant TF expression plays a role in the thrombotic and vascular events in patients with
APS1,3–7. It has been shown that TF synthesis in monocytes and endothelial cells is induced
by aPLA in vitro 7,8. Other stimuli (such as LPS, oxidized LDL and the platelet factor 4-
heparin-antibody complex) that activate monocytes resulting in TF expression also induce
the release of TF-bearing microparticles (MP-TF), both in vitro and in vivo9. Circulating
microparticles are sub-micron sized cellular fragments that may support physiological
hemostasis and/or promote pathological thrombosis. Microparticle activation of coagulation
may be TF-dependent or TF-independent, the latter via assembly of coagulation enzymatic
complexes on the microparticle surface where anionic phospholipids are abnormally
displayed9.
In this study, we measured MP-TF activity in plasma samples from patients with APS and
asymptomatic aPLA to test the hypothesis that MP-TF activity levels are higher in APS
compared to subjects with aPLA without clinical manifestations.
Material and Methods
Study subjects
The subjects for this study were a subset of subjects from the Antiphospholipid Syndrome
Collaborative Registry (APSCORE) (ClinicalTrials.gov:NCT00076713). Samples were
collected between 2002 and 2007. All subjects met serological criteria for definite APS
based on international consensus criteria2. Participants included those who met clinical
criteria for definite APS as well as asymptomatic subjects with aPLA but without clinical
manifestations of APS. In addition, subjects included individuals with and without
underlying systemic lupus erythematosus (SLE) or other autoimmune diseases. APS cases
were defined as individuals meeting both clinical and serological criteria for definite APS2.
Neither subjects with APS nor controls with aPLA were taking warfarin or heparin at
enrollment.
Blood collection and sample preparation
Blood was collected in citrate-anticoagulated tubes by venipuncture using standard sterile
technique. All samples were processed within 4 hours of collection. Blood was centrifuged
at 1,500×g for 10 minutes at 4°C. The platelet poor plasma was carefully removed into
microcentrifuge tubes, taking care not to disturb the buffy coat layer. A second
centrifugation was performed at 2,000×g for 5 minutes to obtain platelet free plasma,
defined as < 2,000 × 109 platelets/L. Plasma aliquots of 200 μL were stored at −80 °C.
Samples were thawed in a water bath at 37°C prior to use.
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Microparticle tissue factor (MPTF) activity assay
A previously described kinetic assay was employed to measure MP-TF activity on the
platelet free (PFP) plasma samples10,11. Briefly, microparticles (MP) were isolated from
plasma via high speed centrifugation (20,000g for 30 minutes at 4°C). The MP pellet was re-
suspended in buffer via mild sonication and incubated with human Factor X, VIIa, and Ca2+
in the presence and absence of a tissue factor blocking antibody. After the addition EDTA
and FXa chromogenic substrate, absorbance measurements were made over time and related
to an Innovin™ standard to calculate MP-TF activity.
Statistics
For comparison between the APS and the aPLA groups, a one-tailed Mann Whitney Test
was performed. A Kruskal-Wallis test was used to compare the APS subgroups. A linear
regression was performed to calculate the R2 to correlate the laboratory values and the MP-
TF activity. All analyses were performed using Graphpad Prism version 5.0 for Windows.
(Graphpad Software, San Diego California, USA). Statistical significance was defined by p
< 0.05.
Results
Study subject clinical and laboratory features
As shown in Table 1, patient groups were well matched for age, ethnicity, and whether
underlying SLE was present or not. As expected, the majority of subjects were female. The
aPLA laboratory data are illustrated in Table 1. Among the group with APS, 8 subjects had
experienced VT (including 1 subject with 2 events), 7 had experienced AT (including 3 with
2 events each), and 7 had experienced PM. Three additional subjects had suffered PM and a
single VT, 4 had experienced PM and a single AT, and 1 subject had suffered PM in
addition to 1 VT and 2 AT events [Table 2].
MP-TF activity in subjects with aPLA compared to patients with APS
Plasma MP-TF activity in patients with APS was significantly higher compared to subjects
with asymptomatic aPLA (p<0.001) [Figure 1A]. However, a considerable degree of overlap
between the groups was apparent. Since the test samples were collected at various times
following the thrombotic or pregnancy-related event in patients with APS, we were unable
to determine whether any heterogeneity in MP-TF activity could be explained by temporal
proximity to the index event. MP-TF activity did not demonstrate any difference between
the APS sub-groups with thrombosis (median (IQR)): 0.12 pg/mL (0.08–0.17)), pregnancy-
related morbidity (0.16 pg/mL (0.11–0.17)) or both (0.14 pg/mL (0.05–0.19)) (p = 0.5865 by
Kruskal-Wallis test). Also of note, MP-TF activity in the subgroup of aPLA with a diagnosis
of SLE (median (IQR): 0.09 pg/mL (0.05–0.13)) was not statistically different compared to
the aPLA subgroup without SLE (median (IQR): 0.09 pg/mL (0.06–0.14)) (p = 0.4871)
[Figure 1B]. Furthermore, there was no difference in MP-TF activity in the 12 subjects with
more than one clinical event (multiple VT, AT or PM or any combination of these events)
compared to the MP-TF activity in the 11 subjects with only a single event (p = 0.5224).
Correlation between laboratory values and MP-TF activity
The correlation between the aPLA laboratory values (IgG and IgM anti-cardiolipin
antibodies and lupus anticoagulant (LAC)) and the MP-TF activity was assessed using linear
regression. There was no significant correlation between MP-TF and any form of aPLA (R2
< 0.02).
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This cross-sectional study examined MP-TF activity in subjects with elevated aPLA with
and without clinical manifestations of APS. Anti-phospholipid antibodies are generally
recognized to be a risk marker for venous or arterial thrombosis, as well for morbidity
during pregnancy1,3. A variety of pathologic mechanisms have been proposed to account for
these complications, including the activation of monocytes and endothelial cells, leading to
de novo synthesis of TF1,3,13. Since TF synthesis during monocyte activation is generally
coupled to the generation of TF-bearing microparticles, we hypothesized that MP-TF levels
would be more elevated in subjects with a history of clinical complications (i.e. APS)
compared to asymptomatic subjects with persistent aPLA only. This hypothesis proved to be
correct, albeit with significant overlap between subjects and controls. Similar degrees of
overlap have however been observed in studies of similar design comparing cancer patients
with and without thrombosis, where the role of MP-TF is currently under active
investigation14. In this study, we did not observe any difference in MP-TF levels between
APS subjects according to the type of clinical complication (thrombosis or PM), nor whether
underlying SLE was present or not in subjects with aPLA.
This study has several limitations. First, we used samples that were collected up to 10 years
previously. Although an effect of prolonged storage on the levels of MP-TF cannot be
excluded, we, and others have observed that most assays for microparticles are relatively
unaffected by storage10,11,14. Specifically, the measured values of MP-TF in normal and
abnormal controls used for internal quality control have shown stable levels over at least 3
years (unpublished data). Although no similarly long-term stored samples from healthy
controls were available for side-by-side comparison in this study, the measured MP-TF
values are comparable to the usually observed range in our laboratory10,13. Second, we did
not have adequate available samples to determine the cellular source of the TF-expressing
MPs, nor whether APS was associated with an increase in MP from multiple cellular
sources, or merely from monocytes or endothelial cells only. Such analysis is generally
performed by flow cytometry, although this technique has its own inherent limitations,
including the inability to enumerate or characterize microparticles with a size below about
0.5 μm9,11,14. In this respect, a functional assay for MP-TF, such as the one used here, has
no theoretical lower size limitations11. Third, we did not investigate the potential
mechanism(s) of monocyte TF induction and vesiculation, although others have shown that
annexin II or the toll-like receptor 4 (TLR4) may be surface receptors responsible for
monocyte activation in response to aPLA4,6,7,12. Finally, this study is retrospective with all
the usual limitations. In particular, we are unable to conclude whether a higher level of MP-
TF is a cause or the result of thrombosis or pregnancy complications in patients with aPLA.
Further prospective studies will be required to determine whether MP-TF is a true
prognostic biomarker of the clinical complications that may ensue in patients with aPLA.
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Figure 1A: MP-TF activity in subjects with anti-phospholipid syndrome (APS) and control
subjects with asymptomatic anti-phospholipid antibodies (APL). Data are presented as
medians and inter-quartile ranges. [***p<0.001].
Figure 1B: MP-TF activity according to sub-groups. Data are presented as medians and
inter-quartile ranges. Abbreviations: Th = history of thrombosis; PM = history of pregnancy-
related morbidity; aPL (−) = asymptomatic with antiphospholipid antibodies but without
SLE; aPL (+) = asymptomatic with antiphospholipid antibodies and SLE.
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Table 1
Demographic features
Subjects with APS (N = 30) Subjects with aPL (N = 72)
Gender
 Male 3 (10.0%) 11 (15.3%)
 Female 27 (90.0%) 61 (84.7%)
Ethnic group*
 Caucasian 22 (73.3%) 50 (69.4%)
 Afro-American 5 (16.7%) 13 (18.1%)
 Hispanic 2 (6.7%) 4 (5.6%)
 Others 1 (3.3%) 4 (5.6%)
Mean age 46.7 (± 12.0) 47.7 (± 12.0)
Primary APS/aPL 11 (33.3%) 19 (26.4%)
APS/aPL secondary to SLE 19 (63.3%) 53 (73.6%)
Elevated IgG (aCL) 12 (40.0%) 21 (29.2%)
Elevated IgM (aCL) 5 (16.7%) 22 (30.6%)
Positive LAC 18 (60.0%) 46 (63.9%)
Median IgG 42 ± 5.5 – 69.5 15.8 ± 4.4 – 73.9
Median IgM 21.8 ± 4.1 – 64.9 24.5 ± 5.4 – 66.5
APS = antiphospholipid antibody syndrome
aPL = antiphospholipid antibodies
SLE = systemic lupus erythematosus
aCL = anticardiolipin antibodies
LAC = lupus anticoagulant
*
Ethnicity of 1 subject with aPL is unknown.
4 subjects with symptomatic APS and 6 subjects with asymptomatic APS had more than one elevated or positive marker.
In the subjects with symptomatic APS: 7 subjects had missing aCL values. 1 subject had only one value of IgG. 3 subjects had only one value of
IgM. 3 subjects had only one value of both IgG and IgM. 4 subjects had only one value of LAC.
In the subjects with asymptomatic APS: 2 subjects had missing aCL values. 1 subject had missing LAC values. 1 subject had only one value of
IgM. 4 subjects had only one value of LAC.
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Table 2
Clinical manifestations in subjects with APS
Number of Subjects
Venous Thrombosis (VT)
 One Event 7
 Two Events 1
Arterial Thrombosis (AT)
 One Event 4
 Two Events 3
Pregnancy Morbidity (PM) 7
PM & one VT 3
PM & one AT 4
PM & 2 AT & 1 VT 1
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